Publicaties
1. Peeters H*, Vander Cruyssen B*, Laukens D, Coucke P, Marichal D, Van Den Berghe M, Cuvelier C, Remaut E, Mielants H, De Keyser F, Vos MD. RADIOLOGICAL SACROILIITIS, A HALLMARK OF SPONDYLITIS, IS LINKED WITH CARD15 GENE POLYMORPHISMS IN PATIENTS WITH CROHN’S DISEASE. Ann Rheum Dis. 2004;63:1131-4. (*equal contribution).
2. Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, Demetter P, Cuvelier C, Van Den Berghe M, Rottiers P, Veys EM, Remaut E, Steidler L, De Keyser F, De Vos M. CARD15 GENE POLYMORPHISMS IN PATIENTS WITH SPONDYLOARTHROPATHIES IDENTIFY A SPECIFIC PHENOTYPE PREVIOUSLY RELATED TO CROHN’S DISEASE. Ann Rheum Dis. 2005;64:930-5.
3. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, Mielants H, Veys EM, Baeten D, De Keyser F. ANTI-CITRULLINATED PEPTIDE ANTIBODIES MAY OCCUR IN PATIENTS WITH PSORIATIC ARTHRITIS. Ann Rheum Dis. 2005;641145-9.
4. Vander Cruyssen B*, Peeters H*, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F. CARD15 POLYMORPHISMS ARE ASSOCIATED WITH ANTI-SACCHAROMYCES CEREVISIAE ANTIBODIES IN CAUCASIAN CROHN’S DISEASE PATIENTS. Clin Exp Immunol. 2005;140:354-9. (*equal contribution)
5. Vander Cruyssen B, Peene I, Cantaert T, Hoffman IE, De Rycke L, Veys EM, De Keyser F. ANTI-CITRULLINATED PROTEIN/PEPTIDE ANTIBODIES (ACPA) IN RHEUMATOID ARTHRITIS: SPECIFICITY AND RELATION WITH RHEUMATOID FACTOR. Autoimmun Rev. 2005;4:468-74. Review.
6. Vander Cruyssen B*, Van Looy S*, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. DAS28 BEST REFLECTS THE PHYSICIAN’S CLINICAL JUDGMENT OF RESPONSE TO INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS PATIENTS: VALIDATION OF THE DAS28 SCORE IN PATIENTS UNDER INFLIXIMAB TREATMENT. Arthritis Res Ther 2005;7:R1063-R1071.(* equal contribution)
7. Van Looy S*, Vander Cruyssen B*, Meeus J, Wyns B, Westhovens R, Durez P, et al. PREDICTION OF DOSE ESCALATION FOR RHEUMATOID ARTHRITIS PATIENTS UNDER INFLIXIMAB TREATMENT. ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE. 2006 Oct;19(7):819-28. (* Equal contribution)
8. Vander Cruyssen B, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F. DIAGNOSTIC VALUE OF ANTI-HUMAN CITRULLINATED FIBRINOGEN ELISA AND COMPARISON WITH FOUR OTHER ANTI-CITRULLINATED PROTEIN ASSAYS. Arthritis Res Ther. 2006;8:R122.
9. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. FOUR-YEAR FOLLOW-UP OF INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH LONGSTANDING REFRACTORY DISEASE: ATTRITION AND LONG-TERM EVOLUTION OF DISEASE ACTIVITY. Arthritis ResTher 2006;8:R112.
10. Van den Bosch F, Vander Cruyssen B, Mielants H. CLINICAL ASSESSMENT IN THE SPONDYLOARTHROPATHIES, INCLUDING PSORIATIC ARTHRITIS. Curr Opin Rheumatol. 2006;18(4):354-8.
11. Vander Cruyssen B, Durez P, Westhovens R, Vastesaeger N, Geldhof A, De Keyser F. RESPONSE TO THE COMMENTARY ‘POOLED INDICES TO MEASURE RHEUMATOID ARTHRITIS ACTIVITY: A GOOD REFLECTION OF THE PHYSICIAN’S MIND’. Arthritis Res Ther. 2006;8(6):406
12. Vander Cruyssen B, De Keyser F, Kruithof E, Mielants H, Van den Bosch F. COMPARISON OF DIFFERENT OUTCOME MEASURES FOR PSORIATIC ARTHRITIS IN PATIENTS TREATED WITH INFLIXIMAB OR PLACEBO. Ann Rheumatic Dis 2007;66(1):138-40.
13. Vander Cruyssen B, Hoffman IE, Peene I, Union A, Mielants H, Meheus L, De Keyser F. PREDICTION MODELS FOR RHEUMATOID ARTHRITIS DURING DIAGNOSTIC WORK-UP: EVALUATION OF COMBINATIONS OF RHEUMATOID FACTOR, ANTI-CITRULLINATED PROTEIN/PEPTIDE ANTIBODIES AND THE HLA SHARED EPITOPE. Ann Rheum Dis. 2007;66(3):364-9.
14. Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J,Steinfeld S, Van den Bosch F, Dewulf L, Vastesaeger N. THE EPIDEMIOLOGY OF ANKYLOSING SPONDYLITIS AND THE COMMENCEMENT OF ANTI-TNF THERAPY IN DAILY RHEUMATOLOGY PRACTICE. Ann Rheum Dis. 2007;66(8):1072-7.
15. Vander Cruyssen B, Nuytinck L, Boullart L, Elewaut D, Waegeman W, Van Thielen M, De Meester E, Lebeer K, Rossau R, De Keyser F. POLYMORPHISMS IN THE FICOLIN 1 GENE (FCN1) ARE ASSOCIATED WITH SUSCEPTIBILITY TO THE DEVELOPMENT OF RHEUMATOID ARTHRITIS. Rheumatology (Oxford). 2007;46(12):1792-5.
16. Vander Cruyssen B, Miltenburg A, Van den Bosch F, Houbiers J, Wittoek R, Boots A, De Keyser F. DECREASE OF DISEASE ACTIVITY UNDER INEFFECTIVE THERAPY IN EARLY, DMARD NAIVE RHEUMATOID ARTHRITIS PATIENTS: ROLE OF ANTIBODY PROFILES AND CARRIAGE OF THE HLA SHARED EPITOPE IN PREDICTING DECREASE OF DISEASE ACTIVITY. J Rheumatol. 2007;34(10):1992-6.
17. Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, Van Calenbergh S, Franck R, Heremans H, De Clercq B, Verbruggen G, Deforce D, Matthys P, Tsuji M, Rottiers P, Elewaut D. A SINGLE EARLY ACTIVATION OF INVARIANT NK T CELLS CONFERS LONG-TERM PROTECTION. J Immunol. 2007;179(4):2300-9.
18. Verbruggen G, Wittoek R, Groeneboer S, Vander Cruyssen B, Goemaere S, Elewaut D. OSTEOCHONDRAL REPAIR IN SYNOVIAL JOINTS. Curr Opin Rheumatol. 2007;19(3):265-71
19. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Müller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G,Elewaut D. A PLANT-DERIVED LIGAND FAVORING MONOMERIC GLUCOCORTICOID RECEPTOR CONFORMATION WITH IMPAIRED TRANSACTIVATION POTENTIAL ATTENUATES COLLAGEN-INDUCED ARTHRITIS. J Immunol. 2008;180(4):2608-15.
20. Vander Cruyssen B, Nogueira L, Van Praet J, Deforce D, Elewaut D, Serre G, de Keyser F. DO ALL ANTI-CITRULLINATED PROTEIN/PEPTIDE ANTIBODY (ACPA) TESTS MEASURE THE SAME? EVALUATION OF DISCREPANCY BETWEEN ACPA TESTS IN RA AND NON-RA PATIENTS. Ann Rheum Dis. 2008;67(4):542-6.
21. Peeters H, Vander Cruyssen B, Mielants H, Vlam K, Vermeire S, Louis E, Rutgeerts P, Belaiche J, De Vos M. CLINICAL AND GENETIC FACTORS ASSOCIATED WITH SACROILIITIS IN CROHN’S DISEASE. J Gastroenterol Hepatol. 2008;23(1):132-7
22. Groeneboer S, Pastoureau P, Vignon E, Vander Cruyssen B, Elewaut D, Verbruggen G. CYCLODEXTRIN POLYSULPHATE PROTECTS ARTICULAR CARTILAGE IN EXPERIMENTAL LAPINE KNEE OSTEOARTHRITIS. Osteoarthritis Cartilage. 2008 Sep;16(9):986-93
23. Van Beneden K, Laroy W, De Keyser F, coppieters K, Hoffman I, Van den Bosch F, Drennan F, Vander Cruyssen B, Rottiers P, Verbruggen G, Contreras R, Callewaert N, Elewaut1 D. REVERSIBLE CHANGES IN SERUM IMMUNOGLOBULIN GALACTOSYLATION DURING THE IMMUNE RESPONSE AND TREATMENT OF INFLAMMATORY AUTO-IMMUNE ARTHRITIS. Ann Rheum Dis. 2009 Aug;68(8):1360-5.
24. Beck I, Vanden Berghe W, Vermeulen L, Bougarne N, Vander Cruyssen B, Haegeman G, De Bosscher K. GLUCOCORTICOIDS INHIBIT NF-B BY INTERFERING WITH THE SUBCELLULAR LOCALIZATION OF MSK1. EMBO J. 2008;27(12):1682-93
25. Smith V, Van Thuyne M, Vander Cruyssen B, Van Praet J, Vermeiren F, Smets H , Houssiau F, Filip De Keyser F. OVERREPRESENTATION OF CONSTRUCTION-RELATED OCCUPATIONS IN MALE PATIENTS WITH SYSTEMIC SCLEROSIS. Ann Rheum Dis. 2008 Oct;67(10):1448-50
26. Smith V, Van Praet J, Vandooren B, Vander Cruyssen B, Naeyaert J-M, Elewaut D, and de Keyser F. RITUXIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: AN OPEN-LABEL CLINICAL AND HISTOPATHOLOGICAL STUDY Ann Rheum Dis. 2010 Jan;69(1):193-7.
27. Wittoek R, De Keyser F, Boonen A, De Vlam K, Vastesaeger N, Mielants H, Verbruggen G, Vander Cruyssen B. PREDICTION MODELS FOR DISEASE: THE EFFECT OF ASSOCIATIONS BETWEEN MARKERS ON CALCULATING THE RISK FOR DISEASE BY LIKELIHOOD RATIO PRODUCTS. Clin Exp Rheumatol. 2009 Mar-Apr;27(2):272-6
28. Boonen A, Vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, Van den Bosch F, Mielants H, Dewulf L, Vastesaeger N.A PRAGMATIC STUDY INTO THE RELATIONSHIP OF SPINAL RADIOGRAPHIC CHANGES WITH CLINICAL CHARACTERISTICS AND FUNCTIONAL OUTCOMES IN ANKYLOSING SPONDYLItis J Rheumatol. 2009 Jun;36(6):1249-55
29. Wittoek R, Vander Cruyssen B, Maheu E, Verbruggen G. CROSS-CULTURAL ADAPTATION OF THE DUTCH VERSION OF THE FUNCTIONAL INDEX FOR HAND OSTEOARTHRITIS (FIHOA) AND A STUDY ON ITS CONSTRUCT VALIDITY. Osteoarthritis Cartilage. 2009 May;17(5):607-12.
30. Elewaut D, Van den Bosch F, Verbruggen F, de Keyser F, Vander Cruyssen B, Mielants H. CLINICAL OBSERVATIONS PROGRAMME IN SPA: DISEASE PARAMETERS, TREATMENT Rheumatol Int. 2009 Jan;29(3):239-50
31. Vander Cruyssen B, Muñoz-Gomariz E, Font P, Mulero J, de Vlam K, Boonen A, Vastesaeger N, Collantes E. EPIDEMIOLOGY OF HIP INVOLVEMENT AND MODELING OF THE NEED FOR HIP PROSTHESIS IN ANKYLOSING SPONDYLITIS. Rheumatology (Oxford). 2010 Jan;49(1):73-81.
32. Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. THE MORBID ANATOMY OF"EROSIVE OSTEOARTHRITIS" OF THE INTERPHALANGEAL FINGER JOINTS. AN OPTIMIZED SCORING SYSTEM TO MONITOR DISEASE PROGRESSION IN AFFECTED JOINTS. Ann Rheum Dis. 2010 May;69(5):862-7 .
33. Georges M, Laukens D, Libioulle C, Sandor C, Mni M, Vander Cruyssen B, Peeters H , Elewaut D, De Vos M. EVIDENCE FOR SIGNIFICANT OVERLAP BETWEEN COMMON RISK VARIANTS FOR CROHN’S DISEASE AND ANKYLOSING SPONDYLITIS [Submitted]
34. Van Praet JT, Vander Cruyssen B, Bonroy C, Smith V, Delanghe J, De Keyser F. VALIDATION OF A NEW SCREENING STRATEGY FOR ANTI-EXTRACTABLE NUCLEAR ANTIGEN ANTIBODIES. Clin Exp Rheumatol. 2009 Nov-Dec;27(6):971-6.
35. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. SEVEN-YEAR FOLLOW-UP OF INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH SEVERE LONG-STANDING REFRACTORY DISEASE: ATTRITION RATE AND EVOLUTION OF DISEASE ACTIVITY. Arthritis
Res Ther. 2010;12(3):R77.
36. Vander Cruyssen B, Durez P, Westhovens R, Kaiser MJ, Hoffman I, De Keyser F; The MIRA Study Group. THE BELGIAN MIRA (MABTHERA IN RHEUMATOID ARTHRITIS) REGISTRY: CLUES FOR THE OPTIMIZATION OF RITUXIMAB TREATMENT STRATEGIES. Arthritis Res Ther. 2010 Sep 10;12(5):R169.
37. Groeneboer S, Lambrecht S, Dhollander A, Jacques P, Vander Cruyssen B, Lories RJ, Devreese K, Chiers K, Elewaut D, Verbruggen G. OPTIMIZED ALKYLATED CYCLODEXTRIN POLYSULPHATES WITH REDUCED RISKS ON THROMBOEMBOLIC ACCIDENTS IMPROVE OSTEOARTHRITIC CHONDROCYTE METABOLISM. Rheumatology (Oxford). 2011 Jul;50(7):1226-35
38. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. PREDICTING THE OUTCOME OF ANKYLOSING SPONDYLITIS THERAPY. Ann Rheum Dis. 2011 Jun;70(6):973-81.
39. Devinck M, Vander Cruyssen B, Lambein K, De Keyser F, Praet M, Brusselle G. MICROSCOPIC POLYANGIITIS INVOLVING THE BREAST. Acta Clin Belg. 2011 Mar-Apr;66(2):139-41.
Hoofdstukken in Boeken
1. Vander Cruyssen B, De Keyser F. RHEUMATOID FACTOR AND ANTICITRULLINATED PROTEIN/PEPTIDE ANTIBODIES. In “The Year in Rheumatic Disorders 5” edited by Madhok, Capell and Luthra. Oxford: clinical publishing; 2006:49-64.
2. Vander Cruyssen B, De Keyser F. NATURAL HISTORY, PROGNOSIS, SOCIOECONMIC ASPECT AND QUALITY OF LIFE OF REACTIVE ARTHRITIS. In “Psoriatic and reactive arthritis” edited by Ritchlin and Fitzgerald. Philadelphia: Elsevier 2006. In press.